JP Morgan Maintains Overweight on Gilead Sciences, Raises Price Target to $170

JP Morgan analyst Chris Schott has maintained an Overweight rating on Gilead Sciences (NASDAQ: GILD) and raised the price target from $160 to $170. This adjustment reflects a positive outlook on the company's performance.